In a welcome move, Krystal Biotech saw its Relative Strength Rating rise from 70 to 77 on Wednesday.
When To Sell Stocks To Lock In Profits And Minimize Losses
IBD's unique rating measures share price movement with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the last 52 weeks compares to all the other stocks in our database.
Over 100 years of market history shows that the market's biggest winners often have an 80 or higher RS Rating in the early stages of their moves. See if Krystal Biotech can continue to rebound and clear that threshold.
While now is not an ideal time to invest, see if the stock manages to form a base and break out.
Earnings growth increased last quarter from 0% to 407%. But revenue gains fell from 879% to 116%. Look for the next report on or around May 6.
Krystal Biotech holds the No. 5 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
